Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (31155)	9/16/2002 8:06:02 PM
From: SemiBull	Respond to of 32384

Ligand Pharmaceuticals To Present at Bear Stearns Conference Tuesday, Sep. 17, 2002, at 11:30 a.m. PT SAN DIEGO--(BUSINESS WIRE)--Sept. 16, 2002--Ligand Pharmaceuticals (Nasdaq: LGND - News), will present at the Bear Stearns Health Care Conference in Phoenix on Tuesday, September 17, at 11:30 a.m. PT. This conference is being web cast by CCBN and can be accessed at Ligand's web site at www.ligand.com. The web cast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network such as America Online's Personal Finance Channel, Fidelity Investments® (Fidelity.com) and others. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com). StreetEvents allows institutional investors to identify, organize, and track the hundreds of conference calls that occur each day during earnings season, to download events of interest to their Outlook calendar, and to RSVP to events online. About Ligand Ligand discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs). -------------------------------------------------------------------------------- Contact: Ligand Pharmaceuticals Michael J. Watts, 858/550-7850 mwatts@ligand.com -------------------------------------------------------------------------------- Source: Ligand Pharmaceuticals